https://openalex.org/T11157
This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia.
@prefix oasubfields: <https://openalex.org/subfields/> .
@prefix openalex: <https://lambdamusic.github.io/openalex-hacks/ontology/> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix skos: <http://www.w3.org/2004/02/skos/core#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
<https://openalex.org/T11157> a skos:Concept ;
rdfs:label "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia"@en ;
rdfs:isDefinedBy openalex: ;
owl:sameAs <https://en.wikipedia.org/wiki/Chronic_lymphocytic_leukemia>,
<https://openalex.org/T11157> ;
skos:broader oasubfields:2716 ;
skos:definition "This cluster of papers focuses on the genomic aberrations, treatment strategies, and prognostic factors associated with chronic lymphocytic leukemia (CLL). It covers topics such as the use of BTK inhibitors (e.g., Ibrutinib), the role of rituximab, TP53 mutations, and the impact of immunoglobulin mutations. Additionally, it explores therapeutic targets and outcomes in patients with Waldenström macroglobulinemia."@en ;
skos:inScheme openalex: ;
skos:prefLabel "Genomic Aberrations and Treatment of Chronic Lymphocytic Leukemia"@en ;
openalex:cited_by_count 1160774 ;
openalex:works_count 88049 .